Epidemic Keratoconjunctivitis Treatment Market Snapshot (2023 to 2033)
The global epidemic keratoconjunctivitis treatment market is expected to garner a market value of US$ 500 million in 2023 and is expected to accumulate a market value of US$ 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Epidemic Keratoconjunctivitis Treatment registered a CAGR of 4% in the historical period 2018 to 2022.
The epidemic keratoconjunctivitis treatment market is a segment of the healthcare industry that deals with the effective management of epidemic keratoconjunctivitis. The epidemic keratoconjunctivitis treatment market offers a range of products and services for its effective management and treatment such as antiviral or steroid eye drops, as well as proper hygiene measures to prevent the spread of the virus. Treatment for EKC typically involves symptom management and reducing the spread of the virus to others.
Report Attribute
Details
Expected Market Value (2023)
US$ 500 million
Anticipated Forecast Value (2033)
US$ 814.45 million
Projected Growth Rate (2023 to 2033)
5% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Epidemic Keratoconjunctivitis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Epidemic Keratoconjunctivitis Treatment reflected a value CAGR of 4% during the historical period, 2018 to 2022.
According to the USA General Population Cross-sectional Study, 2018, around 16 to 49 million Americans have a dry eye disease, accounting for 5% to 15% of the total population. The increasing incidence of Epidemic Keratoconjunctivitis have been reported in schools, offices, and public areas, as well as in institutional settings such as nursing homes and military training facilities. Various factors have been impacting the prevalence of Epidemic Keratoconjunctivitis such as the level of hygiene, the presence of contaminated objects, and the susceptibility of the individual. EKC outbreaks are most common in crowded areas, such as schools, nursing homes, and military training facilities.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Epidemic Keratoconjunctivitis Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Epidemic Keratoconjunctivitis Treatments is fuelling the market growth. Thus, the market for Epidemic Keratoconjunctivitis Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Epidemic Keratoconjunctivitis Treatment Market?
Increased Prevalence of Epidemic Keratoconjunctivitis in Elderly Population to Push the Market Growth
The global market for epidemic keratoconjunctivitis treatment is primarily driven by the increasing prevalence of the disease, the development of new and effective treatment options, advancements in treatment technologies, development of new diagnostic technologies and the availability of more effective treatments. In addition, increased awareness of Epidemic Keratoconjunctivitis, especially amongst geriatric population which is at higher risk of Epidemic Keratoconjunctivitis, has led to a higher healthcare expenditure globally contributing to the growth of the market.
Furthermore, the prevalence of epidemic keratoconjunctivitis is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings. The prevalence of Epidemic Keratoconjunctivitis has increased in recent years due to factors such as increased international travel, urbanization, and the aging of the population, which is expected to drive demand for Epidemic Keratoconjunctivitis treatments.
Antiviral medications, Steroid Eye Drops, Proper Hygiene, Wearing Protective Eyewear are some of the effective measures of reducing the risk of Epidemic Keratoconjunctivitis and other eye infections.
Another factor driving the market is the increase in air pollution in many cities worldwide. A study published by the National Center for Biotechnology Information (NCBI) in 2016 found that the main causes of allergic conjunctivitis are air pollution and weather changes. This is because the conjunctiva is sensitive to environmental particles and has direct contact with the external environment. As a result, an increase in air pollution drives the growth of the global market.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Epidemic Keratoconjunctivitis Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Epidemic Keratoconjunctivitis Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth.
Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Epidemic Keratoconjunctivitis treatment and the availability of diagnostic and therapeutic options.
Region-Wise Insights
How is the Epidemic Keratoconjunctivitis Treatment Market Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling growth of Epidemic Keratoconjunctivitis Treatment in Asia Pacific
The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, with a revenue share of 25% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Epidemic Keratoconjunctivitis Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to health & care. Increasing number of hospitals in India and China makes a promising market for the market worldwide.
What are the Factors Boosting the Market for Epidemic Keratoconjunctivitis Treatment in North America?
Increasing Prevalence of EKC Shaping Landscape for Epidemic Keratoconjunctivitis Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. Factors such as a large and aging population and increasing awareness about Epidemic Keratoconjunctivitis are leading to the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By End-users, Which Segment is Likely to Account for a Significant Share?
Hospital Pharmacy to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacy accounts for the largest market share. Hospital pharmacies have access to antiviral medications, such as acyclovir and trifluridine, which are essential for treating epidemic keratoconjunctivitis.
Furthermore, many hospital pharmacies are covered by insurance plans, which can help patients pay for the cost of their treatment, making it more accessible and affordable.
Startup Scenario
Key startups in the epidemic keratoconjunctivitis treatment market include-
Ocuphire Pharma is a US-based start-up commercializing therapies for eye disorders. The start-up’s lead intravitreal formulation, APX2009, is undergoing preclinical development for the treatment of wet age-related macular degeneration (wAMD). The startup is also working on formulations to treat diabetic retinopathy (DR) and diabetic macular edema.
South Korean start-up PinoTBio offers targeted therapies for ophthalmology and oncology. The startup’s proprietary technology modifies and configures nucleoside analogs to develop targeted therapeutic agents. PinotBio’s pipeline includes therapies for the treatment of glaucoma, as well as solid tumors, and acute myeloid leukemia (AML).
Swiss start-up Oculis uses its solubilizing nanoparticle (SNP) technology to enhance drug solubility in the aqueous tear fluid. OCS-01, the startup’s lead candidate, is undergoing clinical trials for the treatment of diabetic macular edema (DME). Additionally, the startup’s pipeline includes topical treatments for post-cataract surgery inflammation, uveitis, and dry eye.
Market Competition
Key players in the market include pharmaceutical companies such as Novartis International AG, Pfizer Inc, Johnson & Johnson, Roche Holding AG, Bausch + Lomb, Allergan plc, and Alcon, Inc. along with the healthcare providers and technology companies among other global players.
In May 2022 Santen Pharmaceutical received approval for Verkazia from the National Medical Products Administration (NMPA) in China through its legal entity for treating severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and above.
In March 2022, Visus Therapeutics Inc. announced the launch of the first of two pivotal phases 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a topical preservative-free ophthalmic solution for treating presbyopia.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 500 million
Market Value in 2033
US$ 814.45 million
Growth Rate
CAGR of 5% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Drug Class
Route of Administration
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Middle East & Africa
Oceania
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Basilea Pharmaceuticals and Stiefel Laboratories
Renegeron
Sanofi S.A
LeoPharma
Japan Tobacco Inc.
Incyte Corporation
Asana Biosciences
AbbVie Inc.
Santen Pharmaceuticals Co. Ltd.
Jabs Biotech Pvt. Ltd.
Customization
Available Upon Request
Key Segments Profiled in the Epidemic Keratoconjunctivitis Treatment Industry Survey
By Drug Class:
Antihistamines
Anti-Inflammatory
Corticosteroids
By Route of Administration:
Topical
Oral
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What Challenges the Epidemic Keratoconjunctivitis Treatment Market Growth?
The expensive cost of treatment challenges the market growth.
Which Regional Market is Expected to Witness High Growth?
Asia Pacific is expected to witness high growth in 2023.
What is Driving the Epidemic Keratoconjunctivitis Treatment Market?
Increased prevalence of conjunctivitis in the elderly population pushes the market growth.
How did the Market Develop in the Past?
From 2018 to 2022, the global market exhibited a 4% CAGR.
What are the Factors Boosting the Market in North America?
The increasing prevalence of EKC shaping landscape boosts the market in North America.
Table of Content
1. Executive Summary | Epidemic Keratoconjunctivitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antihistamines
5.3.2. Anti-inflammatory
5.3.3. Corticosteroids
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Topical
6.3.2. Oral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Basilea Pharmaceutica and Stiefel Laboratories
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Regeneron
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Sanofi
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. LeoPharma
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Japan Tobacco Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Incyte Corporation
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Asana Biosciences
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. AbbVie Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Santen Pharmaceuticals Co. Ltd.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Jabs Biotech Pvt. Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
